Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Favorable tolerability of asciminib <i>versus</i> ATP-competitive tyrosine kinase inhibitors in the ASC4FIRST study of newly diagnosed patients with chronic-phase chronic myeloid leukemia.

Haematologica·2026
Same author

Immunophenotypic, Cytogenetic, and Molecular Characterization of NUP98-Rearranged Pediatric Myeloid Neoplasms.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2026
Same author

Vibecotamab for measurable residual disease in acute myeloid leukemia and for myelodysplastic syndromes and chronic myelomonocytic leukemia after hypomethylating agent failure: a phase II study.

Journal of hematology & oncology·2026
Same author

Investigational clinical trial agents versus conventional second salvage therapies in patients with relapsed/refractory acute myeloid leukemia.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemia.

Blood·2026

Related Experiment Video

Updated: May 28, 2026

Protocol for MicroRNA Transfer into Adult Bone Marrow-derived Hematopoietic Stem Cells to Enable Cell Engineering Combined with Magnetic Targeting
11:37

Protocol for MicroRNA Transfer into Adult Bone Marrow-derived Hematopoietic Stem Cells to Enable Cell Engineering Combined with Magnetic Targeting

Published on: June 18, 2018

Targeting the bone marrow in Waldenstrom macroglobulinemia.

Irene M Ghobrial1, Yong Zhang, Yang Liu

  • 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. irene_ghobrial@dfci.harvard.edu

Clinical Lymphoma, Myeloma & Leukemia
|November 1, 2011
PubMed
Summary

Waldenstrom macroglobulinemia (WM) involves bone marrow infiltration by malignant cells. This review explores how the bone marrow microenvironment regulates WM cell growth, survival, and spread, identifying key pathways for potential therapies.

More Related Videos

Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice
11:25

Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice

Published on: April 1, 2015

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease
08:05

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease

Published on: March 17, 2020

Related Experiment Videos

Last Updated: May 28, 2026

Protocol for MicroRNA Transfer into Adult Bone Marrow-derived Hematopoietic Stem Cells to Enable Cell Engineering Combined with Magnetic Targeting
11:37

Protocol for MicroRNA Transfer into Adult Bone Marrow-derived Hematopoietic Stem Cells to Enable Cell Engineering Combined with Magnetic Targeting

Published on: June 18, 2018

Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice
11:25

Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice

Published on: April 1, 2015

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease
08:05

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease

Published on: March 17, 2020

Area of Science:

  • Hematology
  • Oncology
  • Cell Biology

Background:

  • Waldenstrom macroglobulinemia (WM) is a rare B-cell lymphoma primarily affecting the bone marrow.
  • Malignant lymphoplasmacytic cells infiltrate the bone marrow, and in some cases, lymph nodes, liver, and spleen.
  • The precise mechanisms of tumor cell homing and retention within bone marrow niches are not fully understood.

Purpose of the Study:

  • To review the critical role of the bone marrow microenvironment in WM pathogenesis.
  • To summarize key regulators of niche-dependent tumor cell proliferation and survival in WM.
  • To highlight potential therapeutic targets within these regulatory pathways for WM treatment.

Main Methods:

  • Literature review focusing on the bone marrow microenvironment in WM.
  • Analysis of signaling pathways, adhesion molecules, and regulatory factors involved in WM cell growth and survival.
  • Synthesis of information on niche-dependent proliferation mechanisms.

Main Results:

  • The bone marrow microenvironment significantly influences WM cell growth, survival, and dissemination.
  • Key regulators identified include chemokines, adhesion molecules, and signaling pathways (Src/PI3K/Akt/mTOR, NF-kB).
  • Micro-RNA regulation also plays a role in niche-dependent tumor proliferation.

Conclusions:

  • Understanding the bone marrow microenvironment's role is crucial for WM pathogenesis.
  • Targeting identified pathways like chemokine signaling, adhesion, and specific molecular signaling cascades offers therapeutic potential.
  • Further clinical investigation of these pathways may lead to improved treatment outcomes for Waldenstrom macroglobulinemia.